000			03667nam a22003735i 4500
001			85724
003			ES-MaUEC
005			20230207040524.0
007			cr nn 008mamaa
008			160812s2016 gw | s |||| 0|eng d
020			_a9783319304724
040			_aES-MaUEC
050		4	_aRS162 _b2016 EB
082	0	4	_a616.12
100	1		_aBaldo, Brian A. _998885 _0Local
245	1	0	_aSafety of Biologics Therapy : _bMonoclonal Antibodies, Cytokines, Fusion Proteins, Hormones, Enzymes, Coagulation Proteins, Vaccines, Botulinum Toxins _cby Brian A Baldo
260			_aCham _bSpringer International Publishing _c2016
300			_a1 recurso en línea (XXI, 610 páginas) _b106 ilustraciones, 89 ilustraciones en color
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_a1: Approved Biologics Used For Therapy and their Adverse Effects -- 2: Monoclonal Antibodies: Introduction -- 3: Monoclonal Antibodies Approved for Cancer Therapy -- 4: Other Approved Therapeutic Monoclonal Antibodies -- 5: Cytokines -- 6: Fusion Proteins -- 7: Peptide Hormones -- 8: Glycoprotein Hormones -- 9: Enzymes Approved for Therapy -- 10: Blood Coagulation -- 11: Vaccines -- 12: Botulinum Neurotoxins -- 13: Biosimilars.
520	3		_aThis long overdue title provides a comprehensive, up-to-date, state-of-the art review of approved biologic therapies, with coverage of mechanisms of action, Indications for therapy, immunogenicity and a detailed examination of adverse effects and safety of the many and diverse therapeutic agents presented in a total of 13 chapters. It is predicted that by 2016, biologics will make up half of the world's 20 top-selling drugs and by 2018, biologic medicine sales will account for almost half of the world's 100 biggest selling drugs. Recombinant proteins dominate the growing list of the more than 200 approved biotherapeutic agents with targeted antibodies, fusion proteins and receptors; cytokines; hormones; enzymes; proteins involved in blood-clotting, homeostasis and thrombosis; vaccines; botulinum neurotoxins; and, more recently, biosimilar preparations, comprising the majority of approved biologics. Written with clinicians, other health care professionals, and researchers in mind, Safety of Biologics Therapy examines, in a single volume, the full range of issues surrounding the safety of approved biologic therapies. A good understanding of the risks and safety issues of modern biologics therapy is increasingly being demanded of all those connected with their development, handling, prescribing, administration and subsequent patient management. In addition to being of great value to clinicians in all branches of medicine, and to nurses, pharmacists and researchers, this book will prove invaluable for students taking undergraduate and graduate courses in the above disciplines and in the biomedical sciences.
710	2		_aSpringerLink (Online service) _0Local _9106996
942			_2lcc _cLE
650		7	_aMedicina _0comprobar BNE19900959047 _2embne _9405021
650		7	_9138557 _aCardiología _0comprobar BNE19900961332 _2embne
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-30472-4 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9783319304724
907			_a.b12950026 _b10-10-17 _c21-11-16
988			_aSpringer_Medicine_2016
998			_am _a_alco _a_vill _b - - _cm _dz _e- _feng _ggw _h0
945			_aRS162 .B353 2016 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11593179 _z06-04-17
999			_c85724 _d85724 _x1